Integra Lifesciences Holdings (IART) EBT (2009 - 2026)

Integra Lifesciences Holdings has disclosed EBT across 18 years of filings, most recently posting $4.7 million for Q2 2026.

• In Q2 2026, EBT rose 100.89% year-over-year to $4.7 million; the TTM figure through Jun 2026 stood at -$179000.0 (up 99.97% YoY), while the FY2025 annual figure was -$563.5 million, down 2989.88% from the prior year.
• EBT came in at $4.7 million for Q2 2026 at Integra Lifesciences Holdings, up from -$2.4 million in the prior quarter.
• In the past five years, EBT ranged from a high of $64.2 million in Q4 2022 to a low of -$531.0 million in Q2 2025.
• Average EBT over 5 years is -$15.8 million, with a median of $4.5 million recorded in 2025.
• Year-over-year, EBT plunged 3396.56% in 2025 and soared 100.89% in 2026.
• Over 5 years, EBT stood at $64.2 million in 2022, then plunged by 55.06% to $28.9 million in 2023, then slipped by 21.89% to $22.5 million in 2024, then plunged by 80.88% to $4.3 million in 2025, then gained by 10.07% to $4.7 million in 2026.
• Per Business Quant data, the three most recent EBT figures were $4.7 million in Q2 2026, -$2.4 million in Q1 2026, and $4.3 million in Q4 2025.